Search results
...Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell...
NBC 17 Raleigh· 7 days ago...commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that new economic model data will be presented on APHEXDA® (motixafortide) for CD34+ hematopoietic stem cell (HSC) mobilization in patients with multiple myeloma at the...